Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EWSR1 Immunotherapy Without or With Pembrolizumab in Ewing Sarcoma and DSRCT
NCT07695311Phase 1Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial in Ewing sarcoma and desmoplastic small round cell tumor (DSRCT) (2 cohorts). Primary endpoints: Safety of EWSR1 immunotherapy at 6 months, Safety of combination therapy at 6 months and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
Ewing sarcomadesmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NCT07695311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07695311.